Golden Ally Lifetech Group, Inc.
AQPW · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.38 | 0.18 | 0.19 |
| FCF Yield | -2.14% | -4.22% | -8.77% | -8.88% |
| EV / EBITDA | -12.86 | -18.24 | -11.22 | -8.34 |
| Quality | ||||
| ROIC | -228.16% | -61.68% | -30.57% | -26.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.27 | 0.78 | 1.04 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 21.24% | 43.46% | -5.48% | 39.27% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | 0.45 | 0.93 | 1.76 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -1,507.97 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -126.46 | -123.67 | -115.26 | -335.65 |